Geron Corporation (Geron) is a clinical-stage biopharmaceutical company developing a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Telomerase is an enzyme that enables cancer cells to maintain telomere length, which provides them with the capacity for limitless cellular replication. Imetelstat is a specific inhibitor of telomerase. The Company operates in one segment, the discovery and development of therapeutic products for oncology. Geron focuses to develop imetelstat to treat one or more hematologic myeloid malignancies, such as myelofibrosis (MF), myelodysplastic syndromes (MDS), or acute myelogenous leukemia (AML). The Company generates its revenues from research support payments under collaboration agreements and milestones, royalties and other revenues from its licensing arrangements.